Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA Breast Cancer study. The data revealed that giredestrant in combination with everolimus significantly reduced the risk of disease progression or death—known as progression-free survival (PFS)—by 44% in the intention-to-treat (ITT) population and by 62% in the ESR1-mutated population, compared to standard-of-care endocrine therapy plus everolimus.
The evERA study is evaluating this investigational combination in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. All participants had previously been treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy.
The giredestrant combination was well tolerated, with no new safety signals observed—including no cases of photopsia. While overall survival data remain immature, a clear positive trend was noted in both the ITT and ESR1-mutated groups.
If approved, giredestrant plus everolimus would become the first and only oral selective estrogen receptor degrader (SERD) combination available for patients in the post-CDK inhibitor setting.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.